Key points are not available for this paper at this time.
Objective:To analyze the clinical efficacy of chemoradiotherapy combined with cell immunotherapy in extensive stage small cell lung cancer.Methods: from March 2022 to 2023, a total of 100 cases were randomized into the control group (n=49) and experimental group (n=51), the control group used conventional chemoradiotherapy, the experimental group with extensive small cell lung cancer chemotherapy combined with cell immunotherapy, comparing the two groups of behavioral ability (Karnofsky, KPS) score, median survival, and 1-year survival rate.Results: Before treatment, there was no significant difference in KPS scores between the two groups (P> 0.05), and after treatment, the KPS score of the experimental group was significantly higher than that of the control group (P <0.05); the median survival and 1-year survival rate of the experimental group were significantly higher than that of the control group (P <0.05).Conclusion: Radiation and chemotherapy combined with extensive stage small cell lung cancer effectively improves the KPS score of patients with extensive stage small cell lung cancer, and improves the median survival period and 1-year survival rate, which is worth popularizing.
Qin et al. (Mon,) studied this question.